Retrospective study assesses biological agents' impact in pediatric FMF, highlighting treatment factors.
Objective Biologic agents have been used in colchicine-resistant familial Mediterranean fever (FMF) patients and in patients with comorbidities including juvenile idiopathic arthritis (JIA). The main aim of our study was to evaluate the use of biological agents in pediatric patients with FMF and to assess the factors influencing the initiation of biological treatment.
No takes yet. Share an insight, caveat, or question.
Pervane et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: